Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

FDA Approves Pomalidomide for Patients with AIDS-Related Kaposi Sarcoma

May 15, 2020
By Hannah Slater
Article

Pomalidomide was approved for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.

The FDA approved pomalidomide (Pomalyst) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative – the only oral agent for this patient population, and the first in more than 20 years.

“[Pomalidomide] has shown positive results in Kaposi sarcoma patients, regardless of their HIV status,” Robert Yarchoan, MD, chief of the HIV and AIDS Malignancy Branch within the Center for Cancer Research of the National Cancer Institute, said in a press release. “Also, it provides a therapy that is taken orally and works by a different mechanism of action than the cytotoxic chemotherapy drugs generally used to treat Kaposi sarcoma.”

Pomalidomide was granted accelerated approval, breakthrough therapy designation, and orphan drug designation based on overall response rates observed in a phase I/II open label, single arm clinical trial (12-C-0047). 

The phase I/II study was conducted to evaluate the safety, pharmacokinetics, and efficacy of pomalidomide in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma, the majority of which have advanced disease.

The primary endpoint of the study was overall response rate (ORR), which included complete response (CR), clinical complete response (cCR), and partial response (PR), as assessed by investigators according to the AIDS Clinical Trial Group (ACTG) Oncology Committee response criteria for Kaposi sarcoma.

In total, 28 patients (18 HIV-positive, 10 HIV-negative) received 5 mg of pomalidomide once daily for 21 of 28-day cycles until disease progression or unacceptable toxicity. Moreover, all HIV-positive patients continued concomitant HAART. Notably, the trial excluded patients with symptomatic pulmonary or visceral Kaposi sarcoma, history of venous or arterial thromboembolism, or procoagulant disorders. 

Additionally, patients received thromboprophylaxis with 81 mg of aspirin once daily throughout therapy. The median time to first response was 1.8 months (0.9 to 7.6). 

Of the overall cohort, the ORR was 71% (95% CI, 51-87) with 14% of patients achieving CR and 57% of patients achieving a PR, respectively. Further, the median duration of response for all patients was 12.1 months (95% CI, 7.6-16.8). In addition, 50% of patients who responded maintained a response at more than 12 months with pomalidomide. 

The most common adverse events (AEs) were decreased absolute neutrophil count or white blood cells, elevated creatinine or glucose, rash, constipation, fatigue, decreased hemoglobin, platelets, phosphate, albumin, or calcium, increased ALT, nausea, and diarrhea. 

AEs were assessed in 28 patients who received treatment with pomalidomide, including maculopapular rash (71%), constipation (71%), fatigue (68%), nausea (36%), diarrhea (32%), cough (29%), dyspnea (29%), peripheral edema (29%), upper respiratory tract infection (29%), muscle spasms (25%), hypothyroidism (21%), dry skin (21%), and chills. 

Grade 3 or 4 AEs included maculopapular rash (3.6%) diarrhea (3.6%), and peripheral edema (3.6%). Grade 3 or 4 laboratory abnormalities (≥5%) worsening from baseline included decreased absolute neutrophil count (50%), decreased phosphate (25%), elevated glucose (7%), and elevated creatine kinase (7%). 

Permanent discontinuation due to an AE occurred in 11% (3/28) of patients who received pomalidomide. No new safety signals were identified, and safety of the agent in Kaposi sarcoma was consistent with the known safety profile of pomalidomide in approved indications. 

“Patients with Kaposi sarcoma have had few options to manage their disease for two decades,” Diane McDowell, MD, vice president of Hematology Global Medical Affairs at Bristol Myers Squibb, said in a press release. “We’re excited that the additional research into pomalidomide in this rare disease area has resulted in our ability to provide a much-needed oral treatment option for patients.”

Continued approval of the agent by the FDA may be dependent on verification and description of clinical benefit in a confirmatory trial. 

The FDA indicated that patients with AIDS-related Kaposi sarcoma should continue HAART for their HIV as recommended by their physician.

Reference:

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma [news release]. Princeton, NJ. Published May 15, 2020. news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-bristol-myers-squib-0. Accessed May 15, 2020. 

Recent Videos
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.